[go: up one dir, main page]

AR023807A1 - Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco - Google Patents

Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco

Info

Publication number
AR023807A1
AR023807A1 ARP000102060A ARP000102060A AR023807A1 AR 023807 A1 AR023807 A1 AR 023807A1 AR P000102060 A ARP000102060 A AR P000102060A AR P000102060 A ARP000102060 A AR P000102060A AR 023807 A1 AR023807 A1 AR 023807A1
Authority
AR
Argentina
Prior art keywords
dry eye
agent
pharmaceutical compositions
compound
macrolid
Prior art date
Application number
ARP000102060A
Other languages
English (en)
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR023807(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of AR023807A1 publication Critical patent/AR023807A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente provee un agente para tratar el ojo seco, que contiene un compuesto macrolido tal como el FK 506, de formula (1). También se describe el uso dedichos macrolidos para la preparacion de las composiciones farmacéuticas destinadas al tratamiento del ojo seco.
ARP000102060A 1999-04-30 2000-04-28 Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco AR023807A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13200999P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
AR023807A1 true AR023807A1 (es) 2002-09-04

Family

ID=22452015

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102060A AR023807A1 (es) 1999-04-30 2000-04-28 Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco

Country Status (23)

Country Link
EP (1) EP1173177B2 (es)
JP (2) JP5036934B2 (es)
KR (1) KR20020015316A (es)
CN (1) CN1190194C (es)
AR (1) AR023807A1 (es)
AT (1) ATE281167T1 (es)
AU (1) AU777915B2 (es)
BR (1) BR0011225A (es)
CA (1) CA2372448A1 (es)
CZ (1) CZ20013769A3 (es)
DE (1) DE60015516T2 (es)
ES (1) ES2232439T3 (es)
HK (2) HK1043321B (es)
HU (1) HUP0200864A3 (es)
IL (1) IL146162A0 (es)
MX (1) MXPA01010988A (es)
NO (1) NO20015288D0 (es)
NZ (1) NZ515339A (es)
PT (1) PT1173177E (es)
TR (1) TR200103119T2 (es)
TW (1) TWI230066B (es)
WO (1) WO2000066122A1 (es)
ZA (1) ZA200108905B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013769A3 (cs) * 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1406700A1 (en) 2001-07-06 2004-04-14 Sucampo AG Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
JP2005536531A (ja) * 2002-08-09 2005-12-02 スキャンポ ファーマシューティカルズ、インコーポレイテッド アレルギー性疾患を処置する為のｆｋ５０６誘導体を含む医薬組成物及びその使用
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
WO2004062669A1 (en) * 2003-01-16 2004-07-29 Sucampo Ag Use of a macrolide compound for treating dry eye
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005032534A1 (ja) 2003-10-06 2005-04-14 Ophtecs Corporation 涙液異常の治療のための眼科用組成物
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
KR20200069261A (ko) * 2017-05-30 2020-06-16 엑시모어 엘티디. 항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법
EP3691654A4 (en) 2017-09-25 2021-11-24 Surface Pharmaceuticals, Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES
SG11202106967QA (en) 2018-12-27 2021-07-29 Surface Ophthalmics Inc Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69016515T2 (de) * 1989-07-05 1995-06-08 Fujisawa Pharmaceutical Co Wässriges flüssiges Mittel zur äusserlichen Anwendung.
US5514686A (en) * 1991-04-26 1996-05-07 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for eye diseases
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US6673807B1 (en) * 1998-04-06 2004-01-06 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
WO1999055332A1 (en) * 1998-04-27 1999-11-04 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
CZ20013769A3 (cs) * 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka

Also Published As

Publication number Publication date
CN1190194C (zh) 2005-02-23
NZ515339A (en) 2004-02-27
ZA200108905B (en) 2002-12-24
EP1173177B1 (en) 2004-11-03
NO20015288L (no) 2001-10-29
CZ20013769A3 (cs) 2002-03-13
ES2232439T3 (es) 2005-06-01
PT1173177E (pt) 2005-03-31
CN1353608A (zh) 2002-06-12
ATE281167T1 (de) 2004-11-15
KR20020015316A (ko) 2002-02-27
JP2012116857A (ja) 2012-06-21
HUP0200864A3 (en) 2004-07-28
HK1046099A1 (zh) 2002-12-27
HK1043321A1 (en) 2002-09-13
AU4142900A (en) 2000-11-17
NO20015288D0 (no) 2001-10-29
EP1173177A1 (en) 2002-01-23
IL146162A0 (en) 2002-07-25
CA2372448A1 (en) 2000-11-09
MXPA01010988A (es) 2004-04-21
JP5036934B2 (ja) 2012-09-26
BR0011225A (pt) 2002-03-19
HUP0200864A2 (hu) 2002-07-29
AU777915B2 (en) 2004-11-04
HK1043321B (en) 2005-07-15
WO2000066122A1 (en) 2000-11-09
TR200103119T2 (tr) 2002-04-22
TWI230066B (en) 2005-04-01
JP2002543132A (ja) 2002-12-17
DE60015516T2 (de) 2005-12-01
DE60015516D1 (de) 2004-12-09
EP1173177B2 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
AR023807A1 (es) Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
BR0215052A (pt) Composições acaricidas e métodos
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2065471T3 (es) Composiciones acuosas antibacterianas que comprenden un tensoactivo y bacteriofagos.
AR006867A1 (es) Composición topica para la piel que comprende un compuesto oxa-diácido, su uso para preparar un medicamento para tratar condiciones de la piel y métodos cosméticos no terapéuticos para el pulido de la piel y para suavizar el cabello que aplican dicho compuesto.
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0200782A (pt) Compostos para o tratamento da isquemia
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
ES2243579T3 (es) Derivados de pirazolopirideno.
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
BR9507730A (pt) Uso de formulações em gel como composições de tratamento
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
ES2194535T3 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contien y su uso como agente parala lucha contra organismos dañinos.
AR004474A1 (es) Compuestos de 10-aminoalifatil-dibenz [b,f]oxepinas antineurodegenerativamente activas, utiles para el tratamiento de estados neurodegenerativos y composiciones farmaceuticas que los contienen
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
ES2144154T3 (es) Derivados de eritromicina a 9-0-oxima dotados de actividad antibiotica.
BR9911559A (pt) Processo para a preparação de um composto, composto, processo para o tratamento de tumores resistentes a medicamento múltiplo, uso de um composto, e, agente e composição para tratar tumores resistentes a medicamento múltiplo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal